Background-Intravascular red cell hemolysis impairs nitric oxide (NO)-redox homeostasis, producing endothelial dysfunction, platelet activation, and vasculopathy. Red blood cell storage under standard conditions results in reduced integrity of the erythrocyte membrane, with formation of exocytic microvesicles or microparticles and hemolysis, which we hypothesized could impair vascular function and contribute to the putative storage lesion of banked blood. Methods and Results-We now find that storage of human red blood cells under standard blood banking conditions results in the accumulation of cell-free and microparticle-encapsulated hemoglobin, which, despite 39 days of storage, remains in the reduced ferrous oxyhemoglobin redox state and stoichiometrically reacts with and scavenges the vasodilator NO. Using stopped-flow spectroscopy and laser-triggered NO release from a caged NO compound, we found that both free hemoglobin and microparticles react with NO about 1000 times faster than with intact erythrocytes. In complementary in vivo studies, we show that hemoglobin, even at concentrations below 10 mol/L (in heme), produces potent vasoconstriction when infused into the rat circulation, whereas controlled infusions of methemoglobin and cyanomethemoglobin, which do not consume NO, have substantially reduced vasoconstrictor effects. Infusion of the plasma from stored human red blood cell units into the rat circulation produces significant vasoconstriction related to the magnitude of storage-related hemolysis.
T ransfusion of blood represents one of the most common medical therapies, with more than 14.5 million packed red blood cell units, or 48.9 U per 1000 persons, administered in the United States per year. 1 It is remarkable that approximately 40% of all critically ill adult patients receive at least 1 unit of packed red blood cells in the intensive care unit, with a mean of 5 U per patient. [2] [3] [4] The 5-unit mark is notable when one considers that this represents 50% of the human blood volume. Since the 1960s, multiple red cell transfusion, or hypertransfusion, has been recognized as a risk factor for acute lung injury. It was first noted during the Vietnam War that "the lungs are a vulnerable target organ to a variety of pathogenetic stimuli," including blood. [5] [6] [7] In recent years, a growing body of literature has demonstrated an increased incidence of adverse clinical outcomes associated with the transfusion of a large number of units or, potentially, with increased storage time of the units. These events include increased risk of infection, renal failure, respiratory failure, multiple organ failure, and death, particularly in physiologically compromised patient populations. 8 -13 This is an active area of investigation, with competing studies suggesting a risk and others suggesting that storage duration risk is confounded by the number of units transfused and the associated severity of illness. 14, 15 Clinical Perspective on p 476
The Food and Drug Administration and American Association of Blood Banks currently permit blood preserved in ADSOL solution to be stored for 42 days. Stored red blood cells undergo a number of morphological and biochemical changes with increased storage time. 16, 17 Morphological changes include reduced deformability, increased osmotic fragility, and spheroechinocyte formation, which are associated with a progressive reduction in intracellular levels of ATP and 2,3-diphosphoglycerate and dropping pH values. In addition, prolonged red cell storage favors oxidant stress conditions, which lead to lipid peroxidation, oxidation of membrane and cytoskeletal proteins, and reduced integrity of the erythrocyte membrane. 16 -19 These and other changes in red blood cell functionality and integrity during storage are commonly referred to as the storage lesion.
There is increasing hemolysis during packed red blood cell storage that increases cell-free plasma hemoglobin over time. 20 -22 Fragmentation and formation of 50-to 100-nm microparticles, which contain a substantial amount of hemoglobin, also occur as red blood cells age. 21, 23, 24 According to current Food and Drug Administration guidelines, at the end of the storage period, only 75% of erythrocytes are required to be recoverable 24 hours after transfusion, which suggests that further hemolysis and microparticle formation occur in vivo after transfusion, although much of this is likely extravascular red cell clearance. These findings are concerning because it is known that free hemoglobin reacts with the vasodilator nitric oxide (NO) in a 1:1 stoichiometric reaction that occurs at a high rate of 6 to 8ϫ10 7 L · mol Ϫ1 · s Ϫ1 . 25 This consumption of NO by cell-free plasma hemoglobin has been shown to cause changes in vascular function in subjects with sickle cell anemia who had plasma heme concentrations as low as 6 mol/L. 26 Approximately half of the observed hemolysis in stored blood is also encapsulated in microparticles, and in theory, on the basis of their small molecular size, microparticles may also exhibit accelerated NO scavenging rates compared with intact erythrocytes. 27 The effect of microparticles on NO scavenging could be especially important, particularly in the microvasculature, where their clearance may not be reflected by systemic clearance rates. Indeed, in a rat model, approximately 90% of red cell microparticles are cleared systemically within 30 minutes of injection and are distributed predominantly into the liver but also throughout multiple organs such as bone, kidneys, skin, and lungs. 28 Hemolysis also decreases NO bioavailability by releasing red cell arginase-1, an enzyme that converts arginine to ornithine, thereby reducing arginine, a substrate for NO synthase. 29, 30 We therefore initiated in vitro chemistry and biophysical studies of stored blood cell-free hemoglobin and microparticles and in vivo physiological studies with infusions of the plasma collected from fresh and aged stored human red cell units to explore whether the formation of microparticles and accumulation of cell-free hemoglobin during in-storage red blood cell hemolysis would increase the rate of NO catabolism and impair endothelial function. The results of these studies suggest new mechanisms for endothelial injury and impaired vascular function associated with the most fundamental of storage lesions, hemolysis.
Methods

Packed Red Blood Cells
Nine randomly selected packed red blood cell units were obtained from the Central Blood Bank, Pittsburgh, PA. These units were nonleukoreduced and preserved in ADSOL solution, which is standard at the University of Pittsburgh Medical Center. Additional units that were leukoreduced were also studied for comparison. The units were stored in a temperature-controlled refrigerator at 1°C to 6°C and sampled weekly over 6 weeks starting at an age of 4 days old. At the end of storage, samples were cultured to exclude bacterial contamination. Samples collected at weekly intervals were centrifuged at room temperature at 2700 g for 20 minutes. The supernatant was stored at Ϫ80°C and later thawed for analysis of free hemoglobin, NO consumption, electron paramagnetic resonance, hemoglobin spectral deconvolution, and arginase-1 assays, as well as for in vivo infusion studies in a rat model as described below.
Cell-Free Plasma Hemoglobin Levels and Spectral Deconvolution of Species
Cell-free plasma hemoglobin was measured by conversion to cyanomethemoglobin with Drabkin's reagent and then by spectrophotometric measurement of absorbance at 540 nm (Beckman Coulter DU 800 UV/visible spectrophotometer, Brea, CA). 31, 32 Hemoglobin concentration and spectra were also measured on an Agilent 8453 UV-visible spectrophotometer (Agilent Technologies, Santa Clara, CA) with 1-cm path-length cuvettes. Concentrations of oxyhemoglobin and methemoglobin in plasma samples were analyzed by deconvolution of the spectrum into components from standard UV-visible spectra of human hemoglobin composed of oxyhemoglobin, methemoglobin, and deoxyhemoglobin in PBS buffer by a least-squares method, as described previously, 33 with some adjustments to correct for the background signal from plasma. Additional experimental details are summarized in the onlineonly Data Supplement.
Nitric Oxide Consumption
The ability of cell-free hemoglobin in the supernatant to scavenge NO was measured with a previously published and validated NO consumption assay with an NO chemiluminescence analyzer (Sievers, Boulder, CO). 34 Additional experimental details are summarized in the online-only Data Supplement.
Arginase-1 Assay
Plasma levels of arginase-1 were measured via ELISA (human arginase 1 ELISA test kit, Hycult Biotechnology BV, Netherlands) according to the manufacturer's instructions and our previous publications. 35 
Electron Paramagnetic Resonance Spin Trap Detection of Reactive Oxygen Species and Free Iron
The spin probe 1-hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine (CPH; Alexis Biochemicals) was added to each stored red blood cell supernatant sample to achieve a final concentration of 200 mol/L. Samples were placed in 50-L glass capillaries and analyzed on a Bruker eScan spectrometer at 37°C and 21% O 2 . Spectra were signal averaged (5 scans over 10 minutes). The instrument settings were as follows: Field sweep 50 Gauss; microwave frequency 9.78 GHz; microwave power 20 mW; modulation amplitude 2 G; conversion time 327 ms; time constant 655 ms; and receiver gain 1ϫ10 5 . To evaluate whether the signal was derived from non-transferrin-bound iron versus reactive oxygen species (ROS), a variety of reagents were added as indicated in Results, including allopurinol, N Gnitro-L-arginine methyl ester, and diphenyleneiodonium chloride, as well as catalase (Sigma, St Louis, MO), CuZn superoxide dismutase (OXIS International Inc, Portland, OR), and deferoxamine mesylate (Sigma).
Detection and Quantification of Red Blood Cell Microparticles
Quantification of microparticles was performed at 14-day intervals for each unit of packed red blood cells. Two microliters of PE-Cy5conjugated glycophorin A (BD Pharmingen, San Jose, CA) was added to 5 L of packed red blood cells. After incubation for 30 minutes in the dark at room temperature, 2 L of FITC-conjugated annexin V was added, followed by 500 L of annexin V binding buffer, per kit instructions (Annexin V-FITC Kit, Beckman Coulter, Bera, CA). After 30 minutes of incubation in the dark at room temperature, analysis was performed with a CyAn ADP cytometer (Beckman Coulter, Miami, FL). An effort was made to acquire a total of 100 000 events per sample at rates not exceeding 10 000 events per second. The cytometer was calibrated to predetermined photomultiplier target channels before each use, with 8-peak Rainbow Calibration Particles (Spherotech, Libertyville, IL; catalog No. RCP-30-5A). Offline spectral compensation and analyses were performed with the VenturiOne analysis package (Applied Cytometry, Dinnington, Sheffield, United Kingdom). Flow cytometric histograms of forward light scatter and fluorescence intensity were displayed on a 4-decade logarithmic scale. Microparticles were quantified as a percent of glycophorin A-positive events. The fraction of hemoglobin contained in microparticles compared with the total hemoglobin in the plasma of stored blood was measured by differential centrifugation at 750 g for 10 minutes at 4°C for the first spin and 37 000 g for 10 minutes for the second spin.
Stopped-Flow Analysis
Hemoglobin was purified and NO-saturated buffers were prepared as described previously. 33 For these experiments, a unit of outdated packed red blood cells with ACD (acid-citrate-dextrose) anticoagulant was purchased from Interstate Blood Bank, Inc (Memphis, TN). The microparticles were isolated as described previously. 36 The absence of red blood cells in the microparticle preparation was confirmed by microscopy. The physical stability of microparticles over time was confirmed by measuring the free hemoglobin concentration in a microparticle preparation that had been left at 4°C for 7 days. Free hemoglobin in a 1-day-old preparation was not detectable by absorbance (intensity in the Soret range).
Stopped-flow experiments of the reaction between NO and free hemoglobin, as well as with red cell-encapsulated hemoglobin and microparticle-encapsulated hemoglobin, were performed as described previously 37 and as described in detail in the online-only Data Supplement. Briefly, 1 syringe of the stopped-flow apparatus was loaded with NO-saturated buffer; another with oxygenated cell-free hemoglobin, red cell-encapsulated hemoglobin, or microparticle-encapsulated hemoglobin; and a third with deoxygenated PBS for dilution purposes. The hemoglobin concentration after mixing was 0.05 mmol/L in heme, and the NO was 1 to 8 times in molar excess to heme. An upper bound for the dead time of the stopped-flow instrument was estimated by a procedure similar to that described by Tonomura et al 38 Photolysis experiments to measure the very fast dioxygenation rate of NO by microparticles compared with cell-free hemoglobin were performed under aerobic conditions similar to those described previously 39 and as described in detail in the online-only Data Supplement for time-resolved absorption measurements. A solution of microparticle-encapsulated hemoglobin or cell-free hemoglobin was mixed 1:1 with a solution of the caged NO donor compound potassium pentachloronitrosyl-ruthenate(II). A quantum yield of NO in each experiment was calculated from each observed reaction rate between cell-free hemoglobin and NO and a 5ϫ10 7 L · mol Ϫ1 · s Ϫ1 bimolecular rate constant for NO scavenging by free oxyhemoglobin, 40 a lower bound that we have established previously. Each obtained value for the yield of NO was used to calculate a corresponding bimolecular rate constant for every observed reaction rate between microparticle-encapsulated hemoglobin and NO. The absence of lysis of microparticles during a photolysis experiment was confirmed by measurement of the absorbance of the supernatant after photolysis, which showed no detectable amount of cell-free hemoglobin. The age of blood used for preparation of vesicles for photolysis experiments was 28 or 33 days.
Rat Vasoactivity Model
The present study was reviewed and approved by the ethics committee for animal subjects of the University of Pittsburgh, Pittsburgh, PA. Wistar male rats (Charles River, Wilmington, MA) with a body weight of 325Ϯ4 g (meanϮSEM) were used in the present study.
Rats were anesthetized with an intraperitoneal injection of a mixture of 90 mg/kg ketamine (Ketaject, Phoenix, St Joseph, MD), 0.5 mg/kg medetomidine (DexDomitor; Pfizer, No. 6295), and 0.005 mg/kg atropine sulfate (Med-Pharmex, Pomona, CA). Details of the experimental setup are summarized in the online-only Data Supplement. A fluid-filled catheter was inserted into the right carotid artery catheter and connected to a pressure transducer (model MLT844, AD Instruments, Colorado Springs, CO), which was connected to a data acquisition system (Powerlab 8/30, AD Instruments) for continuous monitoring of mean arterial blood pressure (MAP) and heart rate. MAP was calculated with the following formula: (systolic blood pressureϪdiastolic blood pressure)/3ϩdiastolic blood pressure. In addition, the jugular vein was cannulated to infuse maintenance anesthesia (ketamine 58 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 in Ringer's solution). The femoral artery was cannulated for blood withdrawal and arterial blood gas sampling. The femoral vein was cannulated for infusion of the packed red blood cell supernatant.
After surgery, the rat was allowed to stabilize for 30 minutes, after which 0.2 mL of blood was drawn for blood gas analysis. As replacement for the drawn blood, 0.2 mL of 6% Hextend in Ringer's lactate (Hospira, Lake Forest, IL) was infused, and the rat was allowed to stabilize for 10 minutes. Subsequently, a volume of 4.95 mL/kg of supernatant from packed red blood cells stored for either 4 or 39 days was infused for approximately 40 minutes at a rate of 7.5 mL ⅐ kg Ϫ1 ⅐ h Ϫ1 . Responses in blood pressure and heart rate were recorded continuously for up to 1 hour after the end of the infusion. Experiments were performed on 5 individual days. Each day, the effect on blood pressure of infusion of packed red blood cell supernatant from the same red cell donor obtained at day 4 and day 39 from the same bag and frozen at Ϫ80°C was determined in 2 separate rats. In the purified human hemoglobin experiments, 1.35 mL/kg of a 13-g/dL hemoglobin solution (or methemoglobin, cyanomethemoglobin) in PBS or 1.35 mL/kg of a 6% Hetastarch was infused for approximately 10 minutes at a rate of 7.5 mL ⅐ kg Ϫ1 ⅐ h Ϫ1 . Additional experiments with infusion of microparticles are summarized in the online-only Data Supplement. 
Statistical Analysis
Results
Accumulation of Plasma Ferrous Oxyhemoglobin (Fe ؉2 -O 2 ) During Red Blood Cell Storage
It is known that progressive low-level hemolysis occurs during standard red blood cell storage in ADSOL preservation solution, a result that we confirmed in our 9 packed red blood cell units ( Figures 1A and 1B) . The cell-free plasma hemoglobin concentration (measured in heme) in supernatants from 9 packed red blood cell units increased over time from a baseline 4-day mean of 11.6Ϯ2.5 mol/L (range 4.6 to 27.7 mol/L) to a 39-day mean value of 81.0Ϯ18.4 mol/L (range 31.0 to 173.3 mol/L). Although our primary analysis was performed in nonleu-koreduced blood, which is the standard at our center, we also performed the experiments in leukoreduced blood. There were no significant differences in the levels of plasma hemoglobin at 39 days of storage (nonleukoreduced 81.0Ϯ18.4 mol/L versus leukoreduced 88.10Ϯ47.84 mol/L). Because low levels of plasma hemoglobin in the ferrous redox state (oxyhemoglobin or deoxyhemoglobin, but not methemoglobin) have the capacity to react with and inactivate NO via the classic dioxygenation reaction (Equation 1), we quantified both the extent of hemolysis and the redox state of the cell-free plasma hemoglobin in supernatant over 39 days in blood from 9 normal blood donors:
Although it might be expected that cell-free plasma hemoglobin would be oxidized to ferric methemoglobin over 39 days of storage, which could not catabolize NO, we have previously found that normal human plasma actively reduces ferric heme to ferrous heme. 34 To explore the redox status of the cell-free plasma hemoglobin during red cell storage, we measured the concentration and percentages of methemoglobin, oxyhemoglobin, and deoxyhemoglobin by UV-visible spectroscopy and least-squares spectral deconvolution. To some surprise, we found that at least 92% of the cell-free plasma hemoglobin remained in the ferrous oxyhemoglobin (Fe ϩ2 -O 2 ) form ( Figures 1C and 1D ). The deconvolution model had a larger fitting error at 4 days of storage because of the lower overall hemoglobin levels and hence lower absorbance signals.
Cell-Free Plasma Hemoglobin and Microparticles Released During Red Blood Cell Storage Stoichiometrically Consume Nitric Oxide via the Dioxygenation Reaction
Ferrous oxyhemoglobin is known to react with NO via the dioxygenation reaction to form methemoglobin and nitrate (Equation 1). 41 Consistent with its redox status measured by spectral deconvolution, we hypothesized that 1 heme would react with and consume 1 NO via this reaction. To measure NO catabolism, we injected supernatant from packed red blood cell units taken at 1-week intervals from 4 to 39 days into an anaerobic solution of NO, generated from the NO donor DETA-NONOate. 34 As shown in Figure 1E , we found that the concentration of NO consumed increased dramatically with red cell storage time. The concentration of NO consumed rose to a similar extent as the concentration of cell-free plasma hemoglobin (concentration measured and reported in terms of heme; Figure 1F ), which suggests a 1:1 reaction stoichiometry. Indeed, the association between measured stored red cell supernatant heme versus NO was highly significant as measured with a linear mixed-effects model (␤-hemeϭ0.98, PϽ0.001; Figure 1G ), which indicates a reaction of 1 mole of heme with 1 mole of NO, consistent with Equation 1. This is interesting because it indicates that hemoglobin remains in the reduced form, capable of NO scavenging, even after 39 days of storage.
In addition to NO dioxygenation reactions that could modulate NO bioavailability, human red cells also contain arginase-1, which metabolizes arginine to ornithine and thus reduces arginine bioavailability for de novo NO synthesis. We found that the stored red cell supernatant contained increasing concentrations of erythrocyte arginase-1, ranging from an average of 280Ϯ69 ng/mL at 4 days of storage to 4633Ϯ631 ng/mL at 39 days of storage ( Figure 1H ). We also found that the amount of cell-free plasma hemoglobin and arginase-1 correlated significantly for each individual unit of packed red blood cells, with R 2 values for 9 units ranging from 0.81 to 0.99 (all PϽ0.015; Table) . Although cell-free hemoglobin to arginase-1 correlation was high for individual units, when data from all units were combined, the R 2 value dropped to 0.51, which indicates that the hemoglobin to arginase-1 ratio varied considerably among donors.
Red Blood Cell Microparticles Inactivate Nitric Oxide at Rates Approaching Cell-Free Hemoglobin
It is known that stored red cells undergo membrane oxidation, damage, and exocytosis to form microparticles. We measured these microparticles using flow cytometry of whole blood without centrifugation, as shown in Figure 2A for a representative unit of packed red blood cells at days 4, 18, and 32. A small proportion of microparticles were evident at 4 days, but they increased dramatically over time. The percent of microparticles in the packed red blood cell units increased with storage duration (median values were 0.24%, 0.37%, and 1.99% of total events at days 4, 18, and 32, respectively; Figure 2B ). The microparticle doubling time was 9.0 days (95% confidence interval 7.7 to 10.7 days, PϽ0.001) as determined by linear regression analysis.
Although increases in microparticles have been appreciated for decades, to the best of our knowledge the ability of these microparticles to react with NO faster than red cells has never been evaluated. Because the dioxygenation reaction of NO with hemoglobin (Equation 1) is limited by compartmentalization within a red blood cell, which is substantially determined by red cell size, we hypothesized that hemoglobin in small microparticles should react with NO much faster than hemoglobin contained in red blood cells. To measure the reaction rates, we first performed time-resolved absorption measurements using a stopped-flow apparatus for red cells and microparticles reacting with NO. Time-resolved absorbance spectra of the reaction of 0.05 mmol/L red cellencapsulated hemoglobin with 0.1 mmol/L NO according to the stopped-flow apparatus is described by an observed rate constant of 2.8 s Ϫ1 (Figure 2C ). Consistent with previous measurements, 37, 42 this gives a bimolecular rate constant on the order of 1000 times slower than for the NO dioxygenation by oxygenated cell-free hemoglobin and illustrates the dramatic slowing of NO dioxygenation by intact red blood cells. Figure 2D displays analogous absorbance data, but for a reaction between 0.05 mmol/L oxyhemoglobin encapsulated in microparticles and 0.05 mmol/L NO. This NO concentra-tion provides the slowest possible reaction rate while allowing complete conversion of microparticle-encapsulated hemoglobin into the ferric form. The only species visible in this case, methemoglobin, is the final product of the reaction. This is because the reaction is much faster than the reaction between red cell hemoglobin and NO, and it is completely over within the dead time of the stopped-flow apparatus. Assuming that it takes at least 2 lifetimes of the reaction until no kinetics may be observed, the lifetime of the dioxygenation of NO by microparticle-encapsulated hemoglobin must be less than or equal to half of the dead time of the stopped-flow instrument. Considering the smallest NO concentration of 0.05 mmol/L used in the reaction, this gives a lower boundary of the dioxygenation bimolecular rate constant for microparticles of at least 2.4ϫ10 6 L · mol Ϫ1 · s Ϫ1 . These studies indicated that the reaction of microparticles with NO was too fast to be observed by stopped flow, similar to the reaction of NO and cell-free hemoglobin.
To more accurately measure the kinetics of the reaction of NO with microparticles, we used a laser photolysis method and compared the results to those obtained with cell-free hemoglobin. A mixture of red cell microparticles or hemoglobin and a solution of the NO donor potassium pentachloronitrosyl-ruthenate(II) ("caged NO") was passed through a quartz flow cell, and the caged NO was released by laser photolysis as described in Methods. Figure 2E shows the time-resolved absorbance data collected from the reaction between 0.02 mmol/L cell-free oxyhemoglobin and a solution of 4 mmol/L caged NO. The NO yield for this reaction was calculated to be 155 mol/L using the observed rate of 7.75ϫ10 Ϫ3 s Ϫ1 and the known biomolecular rate (see Methods) of 5ϫ10 7 L · mol Ϫ1 · s Ϫ1 . Figure 2F shows the absorbance spectra collected from a reaction of 0.02 mmol/L microparticle-encapsulated hemoglobin and the same 4 mmol/L caged NO solution as used in the experiment shown in Figure 2E . The observed rate constant for this data set was 2.74ϫ10 Ϫ3 s Ϫ1 , which gave a bimolecular rate constant of 1.77ϫ10 7 mol ⅐ L Ϫ1 ⅐ s Ϫ1 when calculated with the NO yield from Figure 2E . The average value for the bimolecular rate constant of the dioxygenation reaction between microparticles and NO for all experiments was 1.81Ϯ0.40ϫ10 7 L · mol Ϫ1 · s Ϫ1 (nϭ301; 3 separate experiments). Thus, the dioxygenation reaction between microparticle-encapsulated hemoglobin and NO was only 2.5 to 3 times slower than that for free hemoglobin reacting with NO and approximately 1000 times faster than the reaction with red cell-encapsulated hemoglobin, as measured by photolysis experiments and by stopped flow ( Figure 2G ). The inset graph in Figure 2G shows the 3 biomolecular rate constants on a logarithmic scale, which more clearly highlights the similarity of the cell-free hemoglobin and microparticle NO reaction rates and their large difference from red cell-encapsulated hemoglobin. Hence, it is likely that in vivo microparticles will have an effect on NO bioavailability very similar to that of cell-free plasma hemoglobin. This could be particularly important because microparticles are continuously elaborated after transfusion and are not known to be cleared by haptoglobin. Figure 2E . G, The measured bimolecular rate constants for the dioxygenation of NO by microparticle-and red blood cell (RBC)-encapsulated oxyhemoglobin compared with the rate for cell-free oxyhemoglobin. Inset displays these data on a logarithmic scale.
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Evaluation of Reactive Oxygen Species and Free Iron Formation During Red Blood Cell Storage
We explored oxygen free radical generation in the stored red cell supernatant using electron paramagnetic resonance spin trapping. The hydroxylamine spin probe CPH reacts with ROS and with free iron to form the CP ⅐ radical, which demonstrates a characteristic 3-line electron paramagnetic resonance spectrum ( Figure 3A) . Incubation of the packed red blood cell supernatant with CPH for 10 minutes at 37°C produced a substantive CP ⅐ radical that increased significantly after 18 days of storage ( Figure 3B ). Generation of the CP ⅐ radical was inhibited in a dose-dependent manner by the iron chelator deferoxamine, which suggests free iron as the seminal reactant producing the CP ⅐ signal (Fe 3ϩ ϩCPH3 Fe 2ϩ ϩCP ⅐ ) rather than ROS ( Figure  3C ). To exclude contributions of ROS to the observed CP ⅐ formation and thus further support the interpretation that our signal was indeed dependent on reaction of the spin probe and free iron, we exposed the packed red blood cell supernatants to the antioxidant enzymes catalase and superoxide dismutase, as well as to a battery of inhibitors of enzymatic sources of ROS ( Figure 3D ). Exposure of the 39-day samples to superoxide dismutase or catalase did not alter CP ⅐ radical production, which suggests neither superoxide (O 2 Ϫ ) nor hydrogen peroxidederived hydroxyl radical was responsible for the observed signal. Furthermore, inhibition of NADPH oxidases, xanthine oxidase, aldehyde oxidase, and NO synthases with the global flavin adenine dinucleotide inhibitor diphenyleneiodonium or specific inhibition of these enzymes (allopurinol for xanthine oxidase, raloxifene for aldehyde oxidase, N G -nitro-L-arginine methyl ester for both NO from NO synthase and O 2 Ϫ produced from uncoupled NO synthases) did not alter the CP ⅐ intensity, which confirms free iron as the seminal reactant responsible for our storage-time-dependent CP ⅐ radical formation from the packed red blood cell supernatants. These experiments suggest that effects of stored red cell supernatant on NO levels are not driven by ROS-mediated NO catabolism.
Supernatant From Stored Red Blood Cells Produces Potent In Vivo Vasoconstriction in a Rat Model That Correlates With the Extent of In-Storage Hemolysis
We have identified molecular mediators in stored red cell supernatant that have the potential to substantially impair NO signaling after red blood cell transfusion. To directly test whether these factors modulate vascular reactivity, we infused the stored red cell supernatant from the stored red blood cell units into the rat systemic circulation and compared this with the supernatant from the same human blood donor that was obtained earlier at 4 days of storage. Infusions of stored red cell supernatant for each human donor unit were performed in 2 rats in the same day to control for potential time effects in the model. The mean cell-free plasma hemoglobin concentration of the 5 packed red blood cell units used in this assay was 26Ϯ7 mol/L (range 13 to 45 mol/L) at 4 days of storage and 125Ϯ25 mol/L (range 87 to 185 mol/L) at 39 days of storage. We infused 4.95 mL/kg of stored red cell supernatant into the rats to model the amount infused with a 3-unit red blood cell transfusion into humans. We found that the 4-day-old stored red cell supernatant increased MAP to a mean of 6Ϯ2% above baseline (nϭ5) over the approximately 40-minute period of infusion. All 5 infusions of 39-day-old stored red cell supernatant showed a greater increase in MAP than with infusion of the corresponding supernatant that was obtained at 4 days of storage. The mean increase in normalized MAP after infusion of supernatant obtained Figure 3 . Storage of packed red blood cells induces time-dependent, iron-mediated radical formation. A, Representative electron paramagnetic resonance spectra of 1-hydroxy-3carboxy-2,2,5,5-tetramethylpyrrolidine (CPH) exposed to packed red blood cell supernatants for 10 minutes at 37°C. Spectra represent a signal average of 5 scans from tϭ9 to tϭ10 minutes. B, Mean CP ⅐ signal intensity is displayed vs time (weeks) of storage (nϭ3). *Statistically significant vs week 1 by Bonferroni correction of repeated-measures ANOVA; PϽ0.05. C, Supernatants from 39-day-old packed red blood cells were exposed to 50 mol/L CPH in the presence of increasing concentrations (10 to 200 mol/L) of deferoxamine (DFO). *Statistically significant vs day 39 by Bonferroni correction of repeated-measures ANOVA; PϽ0.05. D, Supernatants from 39-dayold packed red blood cells were exposed to 50 mol/L CPH in the presence of SOD (100 U/mL), catalase (100 U/mL), SOD plus catalase, diphenyleneiodonium (DPI; 100 mol/L), allopurinol (100 mol/L), N G -nitro-L-arginine methyl ester (L-NAME; 100 mol/L), and reloxifene (100 mol/L). Data represent meanϮSEM of at least 3 independent determinations and were not statistically significant. at 39 days of storage was significantly higher (Pϭ0.003), with an increase of 17Ϯ4% (nϭ5) in MAP above baseline (Figures 4A and 4B ). There was a significant correlation (R 2 ϭ0.65) between the amount of hemoglobin present in the supernatant and the percentage increase in blood pressure above baseline ( Figure 4C ).
Microparticle Hemoglobin Content in Stored Blood Plasma Infused in Rat Experiments and Half-Life In Vivo
To quantify the concentration of hemoglobin contained in microparticles in aged blood infused in our experiments, we measured hemoglobin concentrations in microparticles in the 9 U of banked human blood at 6 weeks of storage. In these samples, we evaluated the concentration of microparticles after centrifugation speeds of 2700 g, which was the protocol used to prepare the plasma. Note that quantification of microparticles by flow cytometry in Figures 2A and 2B was measured in uncentrifuged stored units. The levels of microparticles were determined by measuring the hemoglobin concentration by Drabkin's reagent before and after centrifugation at 37 000 g to remove all microparticles. The median percentage of hemoglobin in the plasma contained in microparticles was 10.4% (minimum 3.2%, maximum 23.7%). The meanϮSEM was11.6Ϯ2.2%. The hemoglobin concentration of these microparticles had a median of 9.1 mol/L (minimum 1.1 mol/L, maximum 17.2 mol/L) and a meanϮSE of 8.5Ϯ2.2 mol/L. We also examined the amount of microparticles in 6 U of expired blood that was centrifuged at 750 g and found that a median of 15% (minimum 6%, maximum 40%) of the plasma hemoglobin was contained in microparticles (meanϮSEM measured 17.9Ϯ4.8%). The hemoglobin concentration of these microparticles had a median of 30.2 mol/L (minimum 3.4 mol/L, maximum 56.6 mol/L) and a meanϮSE of 31.9Ϯ9.3 mol/L.
Estimation of microparticle clearance rates for human microparticles infused into the in vivo rat model in the present study was achieved by infusing human red blood cell-derived microparticles into rats (nϭ2) and monitoring for human hemoglobin in the rat plasma at selected time points (before infusion and at 5, 10, 15, 20, 30, and 45 minutes after infusion). Microparticles were quantified by measuring the total human hemoglobin concentrations (by ELISA) and by flow cytometry. We measured the doublepositive events (glycophorin A-PE ϩ and annexin V-FITC ϩ ) in the microparticle size range, enumerated on the basis of their ratio to a known amount of absolute count standard fluorescent microbeads in each sample. As shown in Figure I in the online-only Data Supplement, the half-life of human microparticles in our rat model was less than 15 to 20 minutes, consistent with the observed drop in MAP after cessation of infusion of stored blood plasma. In aggregate, these experiments suggest that the majority of hemoglobin in the rat experiments was in the form of free plasma hemoglobin. However, the effect of microparticles may be greater after transfusion of packed red blood cell units, because these have higher quantities of microparticles, and the transfused red cells will continue to elaborate microparticles after infusion.
Concentrations of Hemoglobin and Redox Status of Hemoglobin Necessary to Induce Vasoconstriction in the Rat Model
Kinetic modeling suggests that levels of plasma hemoglobin as low as 1 mol/L can limit NO bioavailability. 43 These results notwithstanding, doubts have been expressed as to whether such low levels of plasma hemoglobin can significantly modulate in vivo vascular function. 44 Consistent with these theoretical studies, prior experiments have shown reduced NO responsiveness in rabbit tissues infused with as little as 6 mol/L hemoglobin (all concentrations in terms of heme), and we have found that vasodilator responsiveness to NO donor (nitroprusside) is blunted by 80% in patients with sickle cell anemia who have plasma heme concentrations Ն6 mol/L. 26 Despite these data, a number of investigators suggest that these low levels of plasma hemoglobin cannot Rats were stabilized for 30 minutes after surgery, and blood gasses were drawn as indicated (BG 1 and BG 2). Supernatant (1.6 mL) of packed red blood cells stored for either 4 or 39 days was infused for 40 minutes, after which the rats were followed up for 1 hour (nϭ5). B, Change in mean arterial pressure (MAP) over time after packed red blood cell supernatant infusion and 60-minute follow-up. C, Average percentage peak increase in MAP after infusion of packed red blood cell supernatants (PϽ0.003). D, Correlation (solid line) between packed red blood cell supernatant heme concentration and percentage increase in MAP after 40-minute infusion of packed red blood cell supernatant stored for either 4 days (F) or 39 days (f; R 2 ϭ0.65). Each data point was obtained from a separate rat infusion experiment, in a different rat (2 groups of nϭ5). All values are displayed as meanϮSEM. Student t test was used to compare the 2 groups of rats. RBC sup indicates red blood cell supernatant; Avg., average; and conc., concentration.
modulate vascular function. 44 To directly test whether the low concentrations of cell-free plasma hemoglobin present in packed red blood cells are capable of producing vasoconstriction, we infused a human hemoglobin solution over 10 minutes and evaluated the changes in MAP versus the cell-free plasma hemoglobin concentration. As shown in Figure 5A (and inset), infusion of human oxyhemoglobin produces a robust and immediate vasoconstrictive effect, even at levels below 10 mol/L. To determine whether this is related to the NO dioxygenation reaction (Equation 1) versus a colloid osmotic property or the generation of ROS by the ferric form of hemoglobin (methemoglobin or ferryl hemoglobin), we compared infusions of oxyhemoglobin to the same concentration of methemoglobin and cyanomethemoglobin. The latter species is "locked" in a redox inactive form that cannot bind oxygen or participate in redox reactions and represents a more rigorous control for colloid osmotic property effects. As shown in Figure 5B , there were no significant differences between methemoglobin and cyanomethemoglobin, whereas ferrous oxyhemoglobin produced a robust vasoconstriction. Finally, in separate experiments, we infused oxyhemoglobin and serially sampled the plasma from the rat for measurement of NO consumption during continuous infusion. As shown in Figure 5C , infusion of oxyhemoglobin produced a dose-dependent increase in NO consumption within plasma, which was of similar magnitude to the levels of plasma hemoglobin in the circulation, consistent with a mechanism mediated by rapid NO dioxygenation (scavenging). As indicated in Bunn et al, 44 this concept is still very controversial. The present results are the first to show that such low concentrations of heme (6 mol/L) scavenge NO and produce vasoconstriction and are the first to compare this response with an exact hemoglobin control, cyanomethemoglobin.
Discussion
In these studies, we have examined the novel hypothesis that a component of the storage lesion is directly related to in vitro and in vivo hemolysis, with dysregulation of redox pathways in NO signaling mediated by catabolism of NO and arginine. Previous studies have documented substantial hemolysis that increases cell-free plasma hemoglobin as a function of time, reaching 28 mol/L (in heme) in packed red blood cells on average after 35 days of storage in citrate-phosphatedextrose-adenine anticoagulant. 20 Another study reported up to an average of 593 mol/L (in heme) after storage for 35 
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days in citrate-phosphate-dextrose-adenine anticoagulant. 21 More recently, hemolysis was reported to be approximately 0.8% by day 50 of storage. 22 This is approximately 80 mol/L heme and is consistent with our measurements in ADSOL. Given the low threshold for acceptable red blood cell viability (70% after transfusion) in current guidelines, we suggest that intravascular hemolysis and elaboration of microparticles after transfusion may also be considerable. A central problem with hemolysis in stored blood may involve the effects on NO bioavailability. NO plays several major roles in human physiology. It functions as a neurotransmitter and a macrophage-derived host-defense molecule, inhibits platelet aggregation and endothelium adhesion molecule expression, is an antioxidant, and is a potent vasodilator. 45, 46 To elicit its vasodilatory activity, NO must diffuse to the smooth muscle cells and activate soluble guanylyl cyclase. In 1994, Lancaster 47 suggested that the proximity of the endothelium to millimolar concentrations of hemoglobin would severely compromise the efficiency of the NO/soluble guanylyl cyclase pathway. Hemoglobin scavenges NO primarily through a classic dioxygenation reaction in which NO reacts with oxyhemoglobin to form methemoglobin (in which the heme irons are ferric) and nitrate (Equation 1). This reaction, which involves oxidation of the ferrous heme iron (Fe ϩ2 ) to a ferric iron (Fe ϩ3 ), occurs at a rate of 6 to 8ϫ10 7 mol ⅐ L Ϫ1 ⅐ s Ϫ1 . 25, 41, 48 Because of the speed of this reaction, NO can only diffuse approximately 0.07 m (assuming a diffusion constant of 3000 m 2 ⅐ s Ϫ1 and 10 mmol/L hemoglobin). Because NO is freely diffusible, the presence of hemoglobin on one side of the endothelium decreases the concentration of NO on the other side as well.
The reason that endothelium-derived NO does not undergo the dioxygenation reaction (Equation 1) to the extent predicted, based purely on kinetic calculations, is that red blood cell-encapsulated hemoglobin reacts with NO much more slowly than does cell-free plasma hemoglobin. 42,37,49 -53 Three mechanisms contribute to reduced NO scavenging by red blood cells: (1) The rate of the reaction is largely limited by external diffusion of NO to the red blood cell; (2) NO diffusion is partially blocked by a physical barrier across the erythrocyte membrane; and (3) erythrocyte-encapsulated hemoglobin is efficiently compartmentalized in the lumen and does not extravasate into the endothelium and interstitium. None of the 3 mechanisms responsible for reduced NO scavenging by hemoglobin encapsulated in intact red cells pertain to either free hemoglobin in plasma or hemoglobin in microparticles, and all 3 of the mechanisms will break down on hemolysis.
The enhanced ability of cell-free plasma hemoglobin to scavenge NO has been widely attributed to the hypertension, increased systemic and pulmonary vascular resistance, and morbidity and mortality associated with administration of hemoglobin-based oxygen carriers (HbOCs or blood substitutes). 54 -58 Until recently, little attention has been paid to complications due to NO scavenging by cell-free plasma hemoglobin in hemolytic disease, in part because the levels of plasma hemoglobin were so low. 26, 59 However, experiments show reduced NO responsiveness in rabbit tissues infused with as little as 6 mol/L hemoglobin (all concentrations in terms of heme), 60 and we found that vasodilator responsiveness to NO donor (nitroprusside) was blunted by 80% in patients with sickle cell anemia who had plasma heme concentrations Ն6 mol/L. 26 We also demonstrated that intravascular hemolysis leads to vasoconstriction and impairs renal function in a canine intravascular hemolysis model. 61 Indeed, accumulating transgenic animal, large animal, and human epidemiological evidence supports a role for hemolysis in the pathobiology of sickle cell disease and other hemolytic anemias. 29, 30, [61] [62] [63] [64] [65] In the present studies, we confirmed that levels of cell-free plasma hemoglobin during acute infusions below 10 mol/L increased MAP. We further found that this effect was mediated in large part by ferrous oxyhemoglobin, rather than methemoglobin or proteindependent increases in colloid osmotic pressure.
The present studies suggest that a 3-to 4-U packed red blood cell transfusion of aged blood has the potential to inhibit systemic NO signaling. The effects of cell-free plasma ferrous oxyhemoglobin would be compounded by the delivery of red cell microparticles, and the latter may be more important because they would be resistant to clearance by the haptoglobin-CD163 clearance system and through the kidneys. In the present study, using advanced reaction measurements, we hypothesized and confirmed that red cell microparticles scavenge NO rapidly, with the potential to inhibit NO bioavailability in transfused blood.
We recognize that the ongoing steady-state levels of plasma hemoglobin in patients with hemolytic anemias, such as sickle cell disease, likely differ markedly from the situation after red blood cell transfusion, in which plasma hemoglobin levels may be elevated only transiently after even substantial blood transfusions. Given the relatively short half-lives of both free hemoglobin and microparticles derived from transfused stored blood, the overall impact of transfusion on NO depletion and other effects of nonerythrocyte hemoglobin will be transient. Whether a transient inhibition in NO signaling is sufficient to increase the risk of multiorgan dysfunction or hemostatic activation in at-risk populations of patients remains to be determined.
Additional effects of hemolysis in stored blood were evaluated in the present studies and may have contributed to the vasoactive effects we observed. One is the release of red cell arginase-1 into plasma. This enzyme converts arginine to ornithine, thus reducing arginine availability for NO synthesis. 29, 63 Arginasemia has been correlated with hemolysis in a number of human diseases, and high enzyme activity is associated with the development of pulmonary hypertension and increased prospective mortality. Previous work has shown that arginase levels increase in stored blood as a function of time. 66, 67 
Conclusions
On the basis of these studies showing that even low levels of cell-free plasma hemoglobin are sufficient to inhibit endothelial NO signaling and induce vasoconstriction and hypertension, we propose that hemolysis and microparticle formation, as well as arginase-1 release, during storage and after transfusion of aged erythrocytes contribute to decreased NO bioavailability and cardiovascular dysfunction. This effect may represent a contribution to organ injury in the susceptible host receiving multiple red blood cell transfusions. These studies suggest that new therapeutic avenues for red cell storage and transfusion should be studied, such as methods to limit storage-related hemolysis and microparticle formation using ATP-sustaining preservation solutions, cotransfusion of hemoglobin scavenger molecules such as haptoglobin or hemoglobin-binding peptides, red cell membrane-stabilizing agents, and NO signaling/donor agents.
